Toronto Dominion Bank’s Allogene Therapeutics ALLO Stock Holding History

Toronto Dominion Bank’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$66	Hold	27	–	–	﹤0.01%	2068
2025 Q4	$37	Hold	27	–	–	﹤0.01%	2044
2025 Q3	$33	Hold	27	–	–	﹤0.01%	1891
2025 Q2	$31	Hold	27	–	–	﹤0.01%	1770
2025 Q1	$39	Hold	27	–	–	﹤0.01%	1518
2024 Q4	$58	Buy	+27	New	+$67	﹤0.01%	1507
2024 Q3	–	Sell	-27	Closed	-$63	–	1158
2024 Q2	$63	Hold	27	–	–	﹤0.01%	1384
2024 Q1	$121	Hold	27	–	–	﹤0.01%	1317
2023 Q4	$87	Hold	27	–	–	﹤0.01%	1472
2023 Q3	$86	Hold	27	–	–	﹤0.01%	1690
2023 Q2	$0	Hold	27	–	–	﹤0.01%	1486
2023 Q1	$0	Buy	+27	New	+$173	﹤0.01%	1423

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank's ALLO Position: Q1 2026 in Review

Toronto Dominion Bank held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 27 shares worth $66. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

Toronto Dominion Bank first reported a position in ALLO in Q1 2023 and has held it in 12 quarters since. The position peaked at $121 in Q1 2024. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

Toronto Dominion Bank held 27 shares of Allogene Therapeutics worth $66 as of Q1 2026.
Toronto Dominion Bank left its Allogene Therapeutics share count unchanged in Q1 2026.
Allogene Therapeutics made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #2068 holding.
Toronto Dominion Bank first reported a position in Allogene Therapeutics in Q1 2023 and has held it in 12 quarters since.
Toronto Dominion Bank's Allogene Therapeutics position peaked at $121 in Q1 2024.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.